Predictors of clinical outcomes in patients given carvedilol for heart failure

被引:4
|
作者
Greenberg, Barry
Lottes, Sandra R.
Nelson, Jeanenne J.
Lukas, Mary Ann
Fowler, Michael B.
Massie, Barry M.
Abraham, William T.
Gilbert, Edward M.
Franciosa, Joseph A. [1 ]
机构
[1] Cornell Univ, Mt Sinai Sch Med, New York, NY USA
[2] Cornell Univ, Weill Med Coll, New York, NY USA
[3] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[4] GlaxoSmithKline, Philadelphia, PA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[7] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Ohio State Univ, Sch Med, Columbus, OH 43210 USA
[10] Univ Utah, Med Ctr, Salt Lake City, UT 84112 USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2006年 / 98卷 / 11期
关键词
D O I
10.1016/j.amjcard.2006.06.050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk factors for outcomes in heart failure (HF) were derived from populations in clinical trials, at hospital discharge, or in localized geographic or socioeconomic strata before the widespread use of beta blockers. This study observed 4,280 patients in a community-based HF registry for 1 year after completing carvedilol titration. Independent risk factors for death, hospitalization for HF, or hospitalization for cardiovascular reasons other than HF were first identified by age-, gender-, and race-adjusted analyses, then by multivariate analysis adjusted simultaneously for all factors. Over this period, 7% of patients died, 11% were hospitalized for HF, 12% were hospitalized for other cardiovascular reasons, and 27% had >= 1 of these events. The most significant outcome predictors were New York Heart Association class III or IV, history of hospitalization for HF or other cardiovascular reasons, and angina pectoris, all associated with increased odds of having an adverse outcome (all p <= 0.001). The left ventricular ejection fraction was not a significant outcome predictor by multivariate analysis. The odds ratio for an adverse outcome was significantly reduced for patients with hypertensive or idiopathic causes of HF and for those whose physicians had graduated from medical school >= 24 years earlier compared with < 14 years,earlier (all p < 0.005). In conclusion, easily obtained historical information predicts clinical outcomes in patients with HF in the year after initiating carvedilol. In this unselected community population, these historical factors were better predictors of risk than the left ventricular ejection fraction. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1480 / 1484
页数:5
相关论文
共 50 条
  • [41] Treatment of congestive heart failure with carvedilol on pediatric patients
    Mir, T
    Eiselt, M
    Marohn, S
    Laeer, S
    Behn, F
    Scholz, H
    Weil, J
    EUROPEAN HEART JOURNAL, 2000, 21 : 433 - 433
  • [42] Effects of carvedilol in elderly patients with chronic heart failure
    Bristow, MR
    Gilbert, EM
    Packer, M
    Colucci, WS
    Lukas, MA
    Court, M
    Fowler, MB
    Cohn, JN
    CIRCULATION, 1997, 96 (08) : 3228 - 3228
  • [43] Tricuspid regurgitation and clinical outcomes in patients with heart failure
    Aronson, D.
    Lessick, J.
    Mutlak, D.
    Yalonetsky, S.
    Agmon, Y.
    Azzam, Z. S.
    Darawsha, W.
    EUROPEAN HEART JOURNAL, 2014, 35 : 242 - 242
  • [44] Successful carvedilol titration in hypotensive heart failure patients
    Shah, R
    Lawless, CE
    Tamlyn, T
    Kottayil, A
    Malinowska, K
    Durazo-Arvizu, R
    CIRCULATION, 2001, 104 (17) : 718 - 718
  • [45] CLINICAL OUTCOMES IN PATIENTS ON HEMODIALYSIS WITH CONGESTIVE HEART FAILURE
    Zhao, Xinju
    Gan, Liangying
    Niu, Qingyu
    Hou, Fan Fan
    Liang, Xinling
    Chen, Xiao-Nong
    Chen, Yuqing
    Zhao, Junhui
    Mccullough, Kp
    Ni, Zhaohui
    Zuo, Li
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I551 - I552
  • [46] Progenitor Cells and Clinical Outcomes in Patients With Heart Failure
    Tahhan, Ayman Samman
    Hammadah, Muhammad
    Sandesara, Pratik B.
    Hayek, Salim S.
    Kalogeropoulos, Andreas P.
    Alkhoder, Ayman
    Kelli, Heval Mohamed
    Topel, Matthew
    Ghasemzadeh, Nima
    Chivukula, Kaavya
    Ko, Yi-An
    Aida, Hiroshi
    Hesaroieh, Iraj
    Mahar, Ernestine
    Kim, Jonathan H.
    Wilson, Peter
    Shaw, Leslee
    Vaccarino, Viola
    Waller, Edmund K.
    Quyyumi, Arshed A.
    CIRCULATION-HEART FAILURE, 2017, 10 (08)
  • [47] PROGENITOR CELLS AND CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE
    Tahhan, Ayman Samman
    Sandesara, Pratik
    Hayek, Salim
    Hammadah, Muhammad
    Allard-Ratick, Marc
    Kindya, Bryan
    Kalogeropoulos, Andreas
    Kelli, Heval Mohamed
    Topel, Matthew
    Alkhoder, Ayman
    Chivukula, Kaava
    Aida, Hiroshi
    Gafeer, Mohamad Mazen
    Stahl, Eric
    Robert, Heinl
    Abdelhadi, Naser
    Hesaroieh, Iraj
    Naqvi, Humza
    Mahar, Ernestine
    Kim, Jonathan
    Wilson, Peter
    Shaw, Leslee
    Vaccarino, Viola
    Waller, Edmund
    Quyyumi, Arshed
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 928 - 928
  • [48] Clinical Outcomes in Patients on Hemodialysis with Congestive Heart Failure
    Zhao, Xinju
    Gan, Liangying
    Niu, Qingyu
    Hou, Fan Fan
    Liang, Xinlin
    Chen, Xiaonong
    Chen, Yuqing
    Zhao, Junhui
    McCullough, Keith
    Ni, Zhaohui
    Zuo, Li
    KIDNEY DISEASES, 2023, 9 (04) : 306 - 316
  • [49] Predictors of patient-reported outcomes at discharge in patients with heart failure
    Rasmussen, Anne A.
    Johnsen, Soren P.
    Berg, Selina K.
    Rasmussen, Trine B.
    Borregaard, Britt
    Thrysoee, Lars
    Thorup, Charlotte B.
    Mols, Rikke E.
    Wiggers, Henrik
    Larsen, Signe H.
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2020, 19 (08) : 748 - 756
  • [50] Trends, Predictors and Outcomes in Heart Failure Patients undergoing Palliative Care
    Gupta, Navdeep
    Shahreyar, Muhammed
    Muppidi, Vijayadershan
    Gaglianello, Nunzio
    Papp, Mary A.
    Cinquegrani, Michael P.
    CIRCULATION, 2014, 130